Omeprazole Dosing for Infants

Introduction to Omeprazole Use in Infants

The American Academy of Pediatrics and other guideline societies recommend that omeprazole is not used in infants under 2 years of age due to lack of FDA approval and limited safety data 1, 2

FDA approval for omeprazole begins at age 2 years, with weight-based dosing of 10 mg once daily for children 10-20 kg and 20 mg once daily for children ≥20 kg 1, 2
A 4-week-old infant falls well outside the approved age range and represents off-label use with limited safety data 3, 1

For severe, refractory GERD with clear gastrointestinal symptoms, omeprazole dosing would be: starting dose of 0.7 mg/kg/day divided into 2 doses, with dose escalation up to 1.4-2.8 mg/kg/day if inadequate response 4, 5, 2
Practical preparation: compound into 6 mg/mL suspension from capsules mixed with applesauce 2

Serious adverse events, particularly lower respiratory tract infections, occurred more frequently with PPIs than placebo in infants 5, 1

The American Family Physician recommends smaller, more frequent feedings to reduce gastric distension 3
The American Family Physician also recommends thickening formula (if formula-fed), though caution in preterm infants due to necrotizing enterocolitis risk 3
The American Family Physician suggests a maternal elimination diet (exclude milk and egg for 2-4 weeks if breastfeeding) 3
The American Family Physician recommends a trial of extensively hydrolyzed or amino acid-based formula if formula-fed 3
Upright positioning when awake and supervised is also recommended 3

Increased risk of lower respiratory tract infections with PPI use in infants 5, 1
Potential for community-acquired pneumonia, gastroenteritis, and candidemia 3, 1
Long-term use (>2.5 years) associated with enterochromaffin cell hyperplasia in up to 50% of children, though less relevant for short-term infant use 1, 2

Monitor for adverse effects: headaches, diarrhea, constipation, nausea, and respiratory infections 1, 2
Consider referral to pediatric gastroenterology for refractory cases or if diagnostic uncertainty exists 1

The American Thoracic Society, as published in Chest, recommends that PPIs should NOT be used when there are no clinical features of GERD, such as recurrent regurgitation, dystonic neck posturing in infants, or clear signs of acid-mediated disease 6, 7

The American Thoracic Society, as published in Chest, suggests that if PPI therapy is deemed necessary for severe, refractory GERD, the duration should be 4-8 weeks maximum without further evaluation 6, 7, 8

The American Thoracic Society, as published in Chest, recommends re-evaluating response after 4-8 weeks and discontinuing PPI therapy if no clear benefit is observed 6, 7, 8